CBM - Cambrex Corporation

NYSE - Nasdaq Real Time Price. Currency in USD
42.69
+0.18 (+0.42%)
At close: 3:59PM EST

42.66 -0.04 (-0.09%)
After hours: 4:02PM EST

Stock chart is not supported by your current browser
Previous Close42.51
Open42.41
Bid42.67 x 1000
Ask42.68 x 800
Day's Range42.26 - 42.82
52 Week Range35.98 - 69.43
Volume215,842
Avg. Volume439,783
Market Cap1.433B
Beta (3Y Monthly)2.58
PE Ratio (TTM)10.93
EPS (TTM)3.91
Earnings DateFeb 6, 2019 - Feb 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-05-04
1y Target Est62.80
Trade prices are not sourced from all markets
  • Markityesterday

    See what the IHS Markit Score report has to say about Cambrex Corp.

    # Cambrex Corp ### NYSE:CBM View full report here! ## Summary * Bearish sentiment is high and has been increasing * Economic output in this company's sector is contracting ## Bearish sentiment Short interest | Negative Short interest is high for CBM with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting CBM. Sentiment has worsened and traders added to their bearish short positions on January 14. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $3.52 billion over the last one-month into ETFs that hold CBM are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Negative According to the latest IHS Markit Purchasing Managers’ Index (PMI) data, output in the Basic Materialsis falling. The rate of decline is significant relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • CBM or ALKS: Which Is the Better Value Stock Right Now?
    Zacks8 days ago

    CBM or ALKS: Which Is the Better Value Stock Right Now?

    CBM vs. ALKS: Which Stock Is the Better Value Option?

  • Have Insiders Been Selling Cambrex Corporation (NYSE:CBM) Shares?
    Simply Wall St.9 days ago

    Have Insiders Been Selling Cambrex Corporation (NYSE:CBM) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...

  • GlobeNewswire13 days ago

    New Research Coverage Highlights Twenty-First Century Fox, Hill-Rom, Amphenol, Imperva, Maximus, and Cambrex — Consolidated Revenues, Company Growth, and Expectations for 2019

    NEW YORK, Jan. 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire15 days ago

    Cambrex Completes Acquisition of Avista Pharma Solutions

    Cambrex Corporation (CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced that it has completed the acquisition of Avista Pharma Solutions (“Avista”), a contract development, manufacturing, and testing organization, from Ampersand Capital Partners. The transaction, announced on November 20, 2018, strengthens Cambrex’s position as the leading, fully integrated small molecule contract development and manufacturing organization (CDMO) across the entire drug lifecycle.

  • See what the IHS Markit Score report has to say about Cambrex Corp.
    Markit24 days ago

    See what the IHS Markit Score report has to say about Cambrex Corp.

    To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Hedge Funds Are Crazy About Cambrex Corporation (CBM)
    Insider Monkeylast month

    Hedge Funds Are Crazy About Cambrex Corporation (CBM)

    Is Cambrex Corporation (NYSE:CBM) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy league graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]

  • Pharmaceutical ingredient manufacturer plans expansion in High Point
    American City Business Journalslast month

    Pharmaceutical ingredient manufacturer plans expansion in High Point

    Cambrex Corp. (NYSE: CBM) is investing $1 million at its recently expanded 35,000-square-foot site in High Point.

  • See what the IHS Markit Score report has to say about Cambrex Corp.
    Markitlast month

    See what the IHS Markit Score report has to say about Cambrex Corp.

    This means that investors who seek to profit from falling equity prices are currently targeting CBM. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswirelast month

    Cambrex Expands Analytical Capabilities at its High Point, NC Site

    EAST RUTHERFORD, N.J., Dec. 11, 2018 -- Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients.

  • Simply Wall St.last month

    Interested In Cambrex Corporation (NYSE:CBM)? Here’s What Its Recent Performance Looks Like

    Examining Cambrex Corporation's (NYSE:CBM) past track record of performance is a useful exercise for investors. It allows us to reflect on whether the company has met or exceed expectations, which Read More...

  • See what the IHS Markit Score report has to say about Cambrex Corp.
    Markitlast month

    See what the IHS Markit Score report has to say about Cambrex Corp.

    This means that investors who seek to profit from falling equity prices are currently targeting CBM. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • See what the IHS Markit Score report has to say about Cambrex Corp.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Cambrex Corp.

    This means that investors who seek to profit from falling equity prices are currently targeting CBM. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CBM earnings conference call or presentation 8-Nov-18 1:30pm GMT

    Q3 2018 Cambrex Corp Earnings Call

  • The Wall Street Journal2 months ago

    [$$] Cambrex Buying Avista Pharma Solutions From Ampersand for $252 Million

    Corp. on Tuesday said it agreed to buy Avista Pharma Solutions, a contract development, manufacturing and testing organization, from private-equity firm Ampersand Capital Partners for about $252 million. The East Rutherford, N.J.-based life-sciences company said the deal adds early-stage small-molecule development and testing services to its portfolio. Cambrex said it will fund the deal, which it expects to complete before the end of the year, with cash on hand and borrowings under its revolving credit facility, which the company will increase through its accordion feature.

  • GlobeNewswire2 months ago

    Cambrex to Acquire Avista Pharma Solutions, Adding Early Stage API and Finished Dosage Form Development & Testing Services to its Global Contract Development & Manufacturing Network

    -- Conference Call at 8:30 a.m. ET Today -- EAST RUTHERFORD, N.J., Nov. 20, 2018 -- Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and.

  • See what the IHS Markit Score report has to say about Cambrex Corp.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Cambrex Corp.

    This means that investors who seek to profit from falling equity prices are currently targeting CBM. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire2 months ago

    Cleantech Building Materials: Amendment of Loan Facility

    9 November 2018 CLEANTECH BUILDING MATERIALS PLC, NASDAQ FIRST NORTH, COPENHAGEN TICKER:  CBM ISIN:  GBOOBVIVRR47 CLEANTECH BUILDING MATERIALS PLC AMENDMENT OF LOAN FACILITY Cleantech Building Materials ...

  • Cambrex Corp (CBM) Q3 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Cambrex Corp (CBM) Q3 2018 Earnings Conference Call Transcript

    CBM earnings call for the period ending September 30, 2018.

  • Simply Wall St.2 months ago

    What Investors Should Know About Cambrex Corporation’s (NYSE:CBM) Financial Strength

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like Cambrex Corporation (NYSE:CBM), as the company does not have to adhere to strict debt covenants. However, it also faces higher Read More...

  • Cambrex (CBM) Lags Q3 Earnings and Revenue Estimates
    Zacks2 months ago

    Cambrex (CBM) Lags Q3 Earnings and Revenue Estimates

    Cambrex (CBM) delivered earnings and revenue surprises of -16.95% and -18.16%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Cambrex: 3Q Earnings Snapshot

    The East Rutherford, New Jersey-based company said it had profit of 79 cents per share. Earnings, adjusted for non-recurring gains, were 49 cents per share. The life sciences company posted revenue of ...

  • GlobeNewswire2 months ago

    Cambrex Reports Third Quarter 2018 Financial Results

    - Acquired Halo Pharma, broadening capabilities, enhancing revenue growth and expanding customer base - - Conference call at 8:30 a.m. ET on November 8, 2018 - EAST.

  • GlobeNewswire2 months ago

    Cambrex to Announce Third Quarter 2018 Financial Results on November 8, 2018

    EAST RUTHERFORD, N.J., Nov. 05, 2018 -- Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients.

  • Simply Wall St.2 months ago

    Cambrex Corporation (NYSE:CBM): Should The Future Outlook Worry You?

    Based on Cambrex Corporation’s (NYSE:CBM) earnings update in June 2018, analyst consensus outlook seem bearish, with profits predicted to drop by -2.2% next year against the past 5-year average growth Read More...